Time-resolved contrast-enhanced three-dimensional pulmonary MR-angiography: 1.0 M gadobutrol vs. 0.5 M gadopentetate dimeglumine

PURPOSE: To compare contrast characteristics and image quality of 1.0 M gadobutrol with 0.5 M Gd-DTPA for time-resolved three-dimensional pulmonary magnetic resonance angiography (MRA). MATERIALS AND METHODS: Thirty-one patients and five healthy volunteers were examined with a contrast-enhanced time-resolved pulmonary MRA protocol (fast low-angle shot [FLASH] three-dimensional, TR/TE = 2.2/1.0 msec, flip angle: 25 degrees, scan time per three-dimensional data set = 5.6 seconds). Patients were randomized to receive either 0.1 mmol/kg body weight (bw) or 0.2 mmol/kg bw gadobutrol, or 0.2 mmol/kg bw Gd-DTPA. Volunteers were examined three times, twice with 0.2 mmol/kg bw gadobutrol using two different flip angles and once with 0.2 mmol/kg bw Gd-DTPA. All contrast injections were performed at a rate of 5 mL/second. Image analysis included signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) measurements in lung arteries and veins, as well as a subjective analysis of image quality. RESULTS: In patients, significantly higher SNR and CNR were observed with Gd-DTPA compared to both doses of gadobutrol (SNR: 35-42 vs.17-25; CNR 33-39 vs. 16-23; P < or = 0.05). No relevant differences were observed between 0.1 mmol/kg bw and 0.2 mmol/kg bw gadobutrol. In volunteers, gadobutrol and Gd-DTPA achieved similar SNR and CNR. A significantly higher SNR and CNR was observed for gadobutrol-enhanced MRA with an increased flip angle of 40 degrees. Image quality was rated equal for both contrast agents. CONCLUSION: No relevant advantages of 1.0 M gadobutrol over 0.5 M Gd-DTPA were observed for time-resolved pulmonary MRA in this study. Potential explanations are T2/T2*-effects caused by the high intravascular concentration when using high injection rates.     

SPIO-enhanced 2D-TOF MR angiography of the portal venous system: Results of an intraindividual comparison

The purpose of this study was to investigate whether MR angiography (MRA) of the portal venous system may be improved by means of superparamagnetic iron oxides (SPIOs) during accumulation phase imaging and to study the underlying contrast mechanisms. MRA of the portal venous system was performed on 48 patients before and after intravenous injection of a new SPIO (Resovist, Schering AG, Berlin, Germany). Resovist, as a predominantly liver parenchymal darkening agent on T2-weighted MR images with uptake into the reticuloendothelial cell system, was administered intravenously by bolus injection of 8 to 12 μmol Fe/kg body weight. Patients were scanned with breath-hold coronal and axial two-dimensional (2D) time of flight (TOF) MRA (TR = 31.0 msec, TE = 9.8 msec, flip angle (FA) = 50°, and 6.9-second acquisition time per section) sequences. Signal intensity values of liver parenchyma, the portal venous system, and background were obtained for quantitative analysis. The clinical relevance of additional plain and contrast-enhanced MRA studies for surgical planning was assessed by independent reading of three readers. Liver signal-to-noise ratio (SNR) significantly decreased following iv injection of Resovist; however, SNR values of the portal veins or hepatic veins did not change significantly. Visibility of the portal venous system improved significantly (tertiary branches visible: pre in 15.2% versus post in 87.0% of patients). Resovist-enhanced 2D-TOF MRA may improve planning of liver resections by better demonstrating the relationship of central liver lesions and vessels on source images. The decrease in liver SNR at a constant vessel SNR after iv injection of Resovist improves MRA of the liver. SPIO-enhanced 2D-TOF MRA scans are superior to plain 2D-TOF MRA studies and may be added for the workup of preoperative patients.     

MRA of the lower extremities in patients with pulmonary embolism using a blood pool contrast agent: initial experience

PURPOSE: To evaluate the feasibility of blood pool contrast-enhanced magnetic resonance angiography (MRA) to visualize the arterial and venous vessel tree and to detect deep venous thrombosis (DVT) of the lower extremities. MATERIALS AND METHODS: Nine consecutive patients with pulmonary embolism (mean age = 46 +/- 9) were randomized to various doses of NC100150 (between 0.75 and 6 mg of Fe/kg of body weight). A T1-weighted (T1W) 3D gradient recalled echo (GRE) sequence (TE = 2.0 msec, TR = 5.0 msec) was used. Two observers blinded to the dose of contrast agent assessed image quality, contrast attenuation, and appearance of thrombi. RESULTS: Qualitative assessment of overall MRA image quality and semiquantitative vessel scoring revealed good to excellent delineation of venous and arterial vessel segments independent of the dose of NC100150. However, quantitative region of interest analysis revealed a significantly higher signal-to-noise ratio (SNR) in the high-dose group than in the mid- and low-dose groups of NC100150 (P < 0.01). Between dose groups, the SNR was independent of vessel type (artery or vein) and vessel segment localization (proximal or distal). All seven venous thrombi (mean length = 7.2 +/- 0.95 cm) were characterized by a very low signal intensity (SI), which was only 16.6 +/- 7% of the SI in adjacent venous segments (P < 0.0001). CONCLUSION: High-quality MR angiograms of the lower extremities can be obtained using low concentrations of NC100150 in combination with a strong T1W 3D GRE sequence. The obvious delineation of venous thrombi suggests that this technique may be potentially used as a noninvasive "one-stop shopping" tool in the evaluation of thromboembolic disease.     

MR-Angiographie der supraaortalen Gefäße

PURPOSE: To compare high resolution contrast-enhanced MR angiography (MRA) and digital subtraction angiography (DSA) in the assessment of supraaortic vessel stenosis. METHODS: 14 patients with suspicion of cerebrovascular disease or upper limb ischemia underwent selective DSA and high resolution contrast enhanced MRA employing a new Panoramic-Array coil. Stenosis assessment in comparison to DSA followed NASCET criteria. Additionally signal-/noise ratios (SNR) were evaluated to assess contrast enhancement. RESULTS: Diagnostic image quality was achieved in all patients. Sensitivity and specificity for assessing high-grade stenosis of the supraaortic vessels were 100% and 96% respectively. In the assessment of high-grade common or internal carotid artery stenosis sensitivity and specificity was 100%. CONCLUSION: High resolution contrast enhanced supraaortic MRA combined with new coil systems allow for a reliable assessment of stenoses along the whole vessel course including the aortic arch. Previous stent procedures limit its use in postinterventional follow-up.     

Dynamic coronary MR angiography and first-pass perfusion with intracoronary administration of contrast agent

PURPOSE: To evaluate whether dynamic imaging of the coronary arteries can be performed with intracoronary infusion of low-dose gadolinium (Gd)-based contrast agent and assess the effect of long duration and multiple infusions on the image signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR). MATERIALS AND METHODS: Dynamic coronary magnetic resonance (MR) imaging (130 msec/image) and contrast agent first pass myocardial perfusion studies were performed with intracoronary infusions of low-dose Gd-based MR contrast agent on dogs (N = 4) using a fast multislice gradient recalled echo (GRE) sequence. RESULTS: Contrast-enhanced coronary arteries were clearly imaged during infusion periods as long as 2.3 minutes. The SNR and CNR of the contrast-enhanced coronary arteries remained essentially unchanged over multiple consecutive angiographic sessions. In addition, we demonstrated that first pass studies performed with intracoronary injection of MR contrast agent can be used as a means of assessing regional myocardial perfusion. CONCLUSION: These studies demonstrated that, using intracoronary infusion of Gd, coronary magnetic resonance angiography (MRA) can be performed with high temporal resolution, and multiple low-dose slow infusions of Gd-based MR contrast agent can be performed without compromise of the vessel SNR and CNR.     

Free-breathing renal magnetic resonance angiography with steady-state free-precession and slab-selective spin inversion combined with radial k-space sampling and water-selective excitation.

The impact of radial k-space sampling and water-selective excitation on a novel navigator-gated cardiac-triggered slab-selective inversion prepared 3D steady-state free-precession (SSFP) renal MR angiography (MRA) sequence was investigated. Renal MRA was performed on a 1.5-T MR system using three inversion prepared SSFP approaches: Cartesian (TR/TE: 5.7/2.8 ms, FA: 85 degrees), radial (TR/TE: 5.5/2.7 ms, FA: 85 degrees) SSFP, and radial SSFP combined with water-selective excitation (TR/TE: 9.9/4.9 ms, FA: 85 degrees). Radial data acquisition lead to significantly reduced motion artifacts (P < 0.05). SNR and CNR were best using Cartesian SSFP (P < 0.05). Vessel sharpness and vessel length were comparable in all sequences. The addition of a water-selective excitation could not improve image quality. In conclusion, radial k-space sampling reduces motion artifacts significantly in slab-selective inversion prepared renal MRA, while SNR and CNR are decreased. The addition of water-selective excitation could not improve the lower CNR in radial scanning.     

Contrast-enhanced MRA of the brain.

Most sequences for MR angiography (MRA) used today exploit the macroscopic motion of the blood to differentiate vessels from the stationary tissues. An alternative approach to inflow based MRA is contrast enhanced MRA, in which relaxation agents are used to selectively shorten the T1 of the blood below the T1 value of the stationary tissues. We have evaluated cerebral Gd enhanced MRA, comparing it with conventional angiography and noncontrast inflow based MRA. Contrast/enhanced MRAs were obtained at 1.0 T with a 3D FISP sequence with TR/TE/alpha: 35-40 ms, 7-11 ms/TE/25 degrees. Contrast enhancement was obtained by a biphasic injection of a double dose of Gd-DOTA (0.2 mmol/kg) during image acquisition. With the described technique the conspicuity of both cerebral arteries and veins is improved compared to nonenhanced inflow MRA.     

3D pulmonary perfusion MRI and MR angiography of pulmonary embolism in pigs after a single injection of a blood pool MR contrast agent

The purpose of this study was to assess the feasibility of contrast-enhanced 3D perfusion MRI and MR angiography (MRA) of pulmonary embolism (PE) in pigs using a single injection of the blood pool contrast Gadomer. PE was induced in five domestic pigs by injection of autologous blood thrombi. Contrast-enhanced first-pass 3D perfusion MRI (TE/TR/FA: 1.0 ms/2.2 ms/40°; voxel size: 1.3×2.5×4.0 mm³; TA: 1.8 s per data set) and high-resolution 3D MRA (TE/TR/FA: 1.4 ms/3.4 ms/40°; voxel size: 0.8×1.0×1.6 mm³) was performed during and after a single injection of 0.1 mmol/kg body weight of Gadomer. Image data were compared to pre-embolism Gd-DTPA-enhanced MRI and post-embolism thin-section multislice CT (n=2). SNR measurements were performed in the pulmonary arteries and lung. One animal died after induction of PE. In all other animals, perfusion MRI and MRA could be acquired after a single injection of Gadomer. At perfusion MRI, PE could be detected by typical wedge-shaped perfusion defects. While the visualization of central PE at MRA correlated well with the CT, peripheral PE were only visualized by CT. Gadomer achieved a higher peak SNR of the lungs compared to Gd-DTPA (21±8 vs. 13±3). Contrast-enhanced 3D perfusion MRI and MRA of PE can be combined using a single injection of the blood pool contrast agent Gadomer.     

Initial imaging recommendations for Vasovist angiography

Vasovist is a newly developed blood pool contrast agent for MR angiogiography (MRA). It consists of a low molecular weight molecule, chelated to Gadolinium, that strongly binds to plasma proteins, thus increasing its relaxivity and retention time in the vascular system. Due to its high efficiency, a smaller dose compared to existing Extracellular Fluid Contrast Agents is sufficient for diagnostic purposes, resulting in a lower injection volume. With appropriate adjustments of standard extracellular contrast injection protocols, a dynamic phase MRA can be achieved using routine MRA parameters. For extended phase imaging, ('steady-state') starting approximately 3 to 5 min post injection, repetition time (TR) and flip angle may be adjusted for optimization of intravascular signal. Preliminary technical recommendations for the optimization of contrast-enhanced MRA with Vasovist can be deducted from current clinical trial experience in various vessel beds.     

Three-dimensional contrast-enhanced magnetic-resonance angiography of the renal arteries: Interindividual comparison of 0.2 mmol/kg gadobutrol at 1.5 T and 0.1 mmol/kg gadobenate dimeglumine at 3.0 T

The purpose was to evaluate the image quality of high-spatial resolution MRA of the renal arteries at 1.5 T after contrast-agent injection of 0.2 mmol/kg body weight (BW) in an interindividual comparison to 3.0 T after contrast-agent injection of 0.1 mmol/kg BW contrast agent (CA). After IRB approval and informed consent, 40 consecutive patients (25 men, 15 women; mean age 53.9 years) underwent MRA of the renal arteries either at a 1.5-T MR system with 0.2 mmol/kg BW gadobutrol or at a 3.0-T MR scanner with 0.1 mmol/kg BW gadobenate dimeglumine used as CA in a randomized order. A constant volume of 15 ml of these contrast agents was applied. The spatial resolution of the MRA sequences was 1.0 × 0.8 × 1.0 mm³ at 1.5 T and 0.9 × 0.8 × 0.9 mm³ at 3.0 T, which was achieved by using parallel imaging acceleration factors of 2 at 1.5 T and 3 at 3.0 T, respectively. Two radiologists blinded to the administered CA and the field strength assessed the image quality and the venous overlay for the aorta, the proximal and distal renal arteries independently on a four-point Likert-type scale. Phantom measurements were performed for a standardized comparison of SNR at 1.5 T and 3.0 T. There was no significant difference (p > 0.05) between the image quality at 3.0 T with 0.1 mmol/kg BW gadobenate dimeglumine compared to the exams at 1.5 T with 0.2 mmol/kg BW gadobutrol. The median scores were between 3 and 4 (good to excellent vessel visualization) for the aorta (3 at 1.5 T/4 at 3.0 T for reader 1 and 2). For the proximal renal arteries, median scores were 3 for the left and right renal artery at 1.5 T for both readers. At 3.0 T, median scores were 3 (left proximal renal artery) and 4 (right proximal renal artery) for reader 1 and 3 (left/right) for reader 2 at 3.0 T. For the distal renal arteries, median scores were between 2 and 3 at both field strengths (moderate and good) for both readers. The κ values for both field strengths were comparable and ranged between 0.571 (moderate) for the distal renal arteries and 0.905 (almost perfect) for the proximal renal arteries. In the phantom measurements, a 40% higher SNR was found for the measurements at 3 T with gadobenate dimeglumine. High-spatial resolution renal MRA at 3.0 T with 0.1 mmol/kg BW gadobenate dimeglumine yields at least equal image quality compared with renal MRA at 1.5 T with 0.2 mmol/kg BW gadobutrol. Ulrike I. Attenberger and Henrik J. Michaely contributed equally.     

Advances in coronary MRA from vessel wall to whole heart imaging.

Since its introduction, magnetic resonance (MR) imaging has undergone continued technical and methodological development and found numerous practical clinical applications. Cardiac MR imaging is one of the more sophisticated applications of MR, owing to the inherent presence of flow and motion and specific anatomy. Among the different categories of cardiac MR imaging, coronary MR angiography (MRA) places particularly high demands on planning, spatial resolution, high signal-to-noise ratio (SNR), and precise cardiac and respiratory motion correction. However, recent advances in hardware, MR sequences, and motion detection techniques have made it possible to perform coronary MRA that includes volumetric acquisition of the entire heart as well as imaging of the vessel walls on a submillimeter scale within a clinically acceptable scan time. We discuss from a technical perspective some of the milestones leading to the current state of coronary MR imaging and outline recent developments that will further advance coronary MR imaging. We discuss planning procedure, contrast preparation mechanisms and MR sequences, motion correction, high-resolution coronary artery and vessel wall imaging, and fast volumetric scanning techniques. Although MR imaging has certain limitations in providing simultaneous speed, resolution, and high SNR, it nonetheless offers a dedicated scanning procedure that addresses most clinically relevant questions in the diagnosis of ischemic heart disease.     

Intraindividual comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine for time-resolved contrast-enhanced three-dimensional magnetic resonance angiography of the upper torso

PURPOSE: To compare the signal characteristics and bolus dynamics of 1.0 M gadobutrol and 0.5 M Gd-DTPA for time-resolved, three-dimensional, contrast-enhanced (CE) MRA of the upper torso. MATERIALS AND METHODS: Ten healthy volunteers were examined with time-resolved three-dimensional CE-MRA (scan time per three-dimensional data set: 0.86 second; voxel size: 3.6 x 2 x 6.3 mm(3)). Each volunteer underwent eight individual examinations after intravenous injection of 0.05 and 0.1 mmol/kg body weight (b.w.) of 1.0 M gadobutrol and 0.5 M Gd-DTPA using two injection rates (2.5 and 5 mL/second). The data analysis included quantitative measurements of the peak signal-to-noise ratio (SNR) and bolus dispersion (full width at half maximum (FWHM)) in the pulmonary artery, left atrium, and thoracic and abdominal aortas. RESULTS: No significant differences in the peak SNR and bolus dispersion were observed between gadobutrol and Gd-DTPA for all dose levels and injection rates in any of the vascular segments. For both contrast agents a dose of 0.1 mmol/kg b.w. injected with 5 mL/second achieved the highest SNR in all vascular segments. CONCLUSION: For the imaging parameters used in this study, higher-concentrated gadolinium chelates offer no relevant advantages for time-resolved three-dimensional CE-MRA of the upper torso.     

The active magnetic resonance imaging stent (AMRIS): initial experimental in vivo results with locally amplified MR angiography and flow measurements

RATIONALE AND OBJECTIVES: Magnetic resonance (MR) is limited by artifacts in vessels after stenting. An active MR imaging stent (AMRIS) allows for artifact-free imaging with local improvement in signal-to-noise ratio (SNR). In a rabbit model, we evaluated the imaging properties by MR angiography (MRA) and flow measurements. METHODS: The AMRIS was placed in the abdominal aorta of five rabbits. At 1.5 T, MRA (three-dimensional fast low-angle shot) was performed before and after intravenous injection of an iron oxide-based, blood-pool contrast medium (dose, 50 micromol Fe/kg), and flow measurements were performed (electrocardiographically triggered phase-contrast cine gradient-echo sequence). Mean SNRs were calculated and flow volume curves were generated. RESULTS: The SNR was 6.0 +/- 0.6 (outside the stent) versus 12.3 +/- 1.1 (inside the stent, P < 0.05) for plain MRA, 21.2 +/- 0.6 versus 40.6 +/- 5.2 (P < 0.05) for contrast-enhanced MRA, and 5.4 +/- 0.4 versus 13.7 +/- 2.1 (P < 0.05) for the magnitude images of flow measurements. Flow volume curves within and distal to the stent were comparable. CONCLUSIONS: By using the AMRIS as a vascular stent, the stented vessel segment can be examined with enhanced signal intensity on MRI.     

A vascular stent as an active component for locally enhanced magnetic resonance imaging: initial in vivo imaging results after catheter-guided placement in rabbits

RATIONALE AND OBJECTIVE: A vascular stent constructed as a high frequency resonator improves the local signal-to-noise ratio at magnetic resonance (MR) imaging. After catheter placement and intravascular expansion, the stent can be used as an inductively coupled coil for MRI. The imaging properties of this balloon-expandable active MRI stent (AMRIS) were evaluated after x-ray fluoroscopy guided placement in the abdominal aorta of five rabbits using MR angiography (MRA) and flow measurements. METHODS: The AMRIS was implanted in the abdominal aorta of five rabbits using a balloon catheter inserted through the common carotid artery. The rabbits were examined by MRA (3D fast low-angle shot) at 1.5 tesla before and after intravenous injection of an iron-oxide-based blood pool contrast medium (dose 50 micro mol Fe/kg) and flow measurements (ECG-triggered phase contrast cine gradient-echo sequence). Signal-to-noise ratios (SNR) were calculated and flow volume curves were generated. The in-stent increase in temperature was measured in vitro using a fiberoptic thermometry system. RESULTS: The SNR was 5.0 +/- 0.6 outside the stent and 23.2 +/- 14.1 within the stent ( < 0.0 5) in plain MRA, 19.5 +/- 5.0 outside and 30.7 +/- 8.2 within the stent ( < 0.05) in contrast enhanced MRA, and 5.8 +/- 1.6 and 13.9 +/- 5.9, respectively ( < 0.05) in the magnitude images of the flow measurements. Flow volume curves within and distal to the stent were comparable. CONCLUSIONS: The expandable active MRI stent produces local signal enhancement in MRA and MR flow measurements after catheter placement and thus may improve assessment of the stented vessel segment by MR imaging.     

3.0 Tesla magnetic resonance angiography of endovascular aortic stent grafts: phantom measurements in comparison with 1.5 Tesla

RATIONALE AND OBJECTIVES: This study evaluated different stent grafts by 3 T magnetic resonance angiography (MRA) with respect to lumen visibility, susceptibility-induced signal loss, and type of stent artifacts compared with 1.5 T MRA in a phantom model. METHODS: Six different stent-grafts (tube: n = 3, bifurcated: n = 3) were evaluated by 3 T and 1.5 T MRA using a tube phantom. MRA was performed using T1-weighted sequences at both systems with comparable parameters (3T: TR 5.4/TE 2.0/FA 30 degrees, 1.5 T: TR 6.2/TE 2.2/FA 30 degrees). A blind study of the image quality, including artifacts, was performed by 3 radiologists. Furthermore, signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) values were calculated. Statistical analysis was performed with Student's t test (P < 0.05). RESULTS: One Elgiloy stent graft showed almost a complete intraluminal signal loss at 1.5 and 3 T. All other models could be evaluated by both systems by MRA, resulting in a favorable lumen visibility (score: 1) for prostheses made of nitinol. Scores for overall image quality and artifacts were the same for both MR systems. SNR and CNR values of the stented part of the vessel phantom increased from 320 +/- 33 to 618 +/- 40 and from 306 +/- 34 to 596 +/- 40 at 3 T when compared with 1.5 T, resulting in a significant signal gain of 93% at the higher field strength. CONCLUSIONS: 3 Tesla MRA of aortic stent grafts in a phantom model demonstrates an increase in SNR and CNR when compared with 1.5 T. However, the magnitude of imaging artifacts as well as coherent intraluminal signal loss within the stent does not increase equally in both MR systems.     

3D contrast-enhanced MR angiography

Safe, fast, accurate contrast arteriography can be obtained utilizing gadolinium (Gd) and 3D MR data acquisition for diagnosing vascular diseases. Optimizing contrast enhanced MRA (CE MRA), however, requires understanding the complex interplay between Gd injection timing, the Fourier mapping of 3D MR data acquisition and a multitude of parameters determining resolution, anatomic coverage, and sensitivity to motion artifacts. It is critical to time the bolus peak to coincide with central k-space data acquisition, which dominates image contrast. Oversampling the center of k-space allows reconstruction of multiple 3D acquisitions in rapid succession to time-resolve the passage of the contrast bolus. Parallel imaging increases resolution, shortens scan time and compresses the center of k-space into a shorter period of time, thereby minimizing motion and timing artifacts. Absence of ionizing radiation allows MRA to be repeated and combined with additional sequences to more fully characterize anatomy, flow, and physiology. Utilizing stepping table technology and thigh compression, whole body MRA is possible with a single contrast injection. As MR technology continues to advance, CE MRA becomes better and simpler to perform, increasing its efficacy in the diagnosis and management of vascular diseases.     

Three-dimensional isotropic contrast-enhanced MR angiography of the carotid artery using sensitivity-encoding and random elliptic centric k-space filling: technique optimization

We present a study that helped optimize a three-dimensional isotropic contrast-enhanced MR angiographic (CE-MRA) technique, using sensitivity encoding (SENSE) and random elliptic centric k-space filling. Two-dimensional gradient-echo sequence (TR/TE/flip angle 3.4/0.97/40°) was used to generate time–intensity curves in porcine carotid arteries for a fixed dose of Gd-DTPA (0.02 mmol/kg) at the following intravenous injection rates: 0.1, 0.3, 0.5, 1.0, 1.5, 2.0, and 3.0 ml/s. The time of contrast arrival and time to peak were recorded. Based on the time–intensity curves, three-dimensional high-resolution isotropic (1 mm³) CE-MRA sequence (TR/TE/flip angle: 4.9/2.4/30°), using SENSE (reduction factor of 2) and random elliptic centric k-space filling, was initiated twice for each of the above injection rates: first at the time of contrast arrival and second at the time of peak contrast. The three-dimensional CE-MRA images were analyzed for artifacts, signal-to-noise ratio, and venous contamination. For the three-dimensional CE-MRA acquisitions that were initiated at the time of contrast arrival, there was a gradual improvement in signal-to-noise ratio (SNR) in the carotid arteries with increasing injection rate. The same trend was not observed for the acquisitions that were initiated at the time of peak contrast. SENSE combined with random elliptic k-space acquisition in CE-MRA allows for higher SNR with fewer ringing artifacts at faster contrast injection rates.     

Contrast-enhanced three-dimensional pulmonary perfusion magnetic resonance imaging: intraindividual comparison of 1.0 M gadobutrol and 0.5 M Gd-DTPA at three dose levels

RATIONALE AND OBJECTIVES: To compare 1.0 M gadobutrol and 0.5 M Gd-DTPA for contrast-enhanced three-dimensional pulmonary perfusion magnetic resonance imaging (3D MRI). MATERIALS AND METHODS: Ten healthy volunteers (3 females; 7 males; median age, 27 years; age range, 18-31 years) were examined with contrast-enhanced dynamic 3D MRI with parallel acquisition technique (FLASH 3D; reconstruction algorithm: generalized autocalibrating partially parallel acquisitions; acceleration factor: 2; TE/TR/alpha: 0.8/1.9 milliseconds/40 degrees; FOV: 500 x 375 mm; matrix: 256 x 86; slab thickness: 180 mm; 36 partitions; voxel size: 4.4 x 2 x 5 mm; TA: 1.48 seconds). Twenty-five consecutive data sets were acquired after intravenous injection of 0.025, 0.05, and 0.1 mmol/kg body weight of gadobutrol and Gd-DTPA. Quantitative measurements of peak signal-to-noise ratios (SNR) of both lungs were performed independently by 3 readers. Bolus transit times through the lungs were assessed from signal intensity time curves. RESULTS: The peak SNR in the lungs was comparable between gadobutrol and Gd-DTPA at all dose levels (15.7 vs. 15.5 at 0.1 mmol/kg bw; 12.9 vs. 12.5 at 0.05 mmol/kg bw; 7.6 vs. 8.9 at 0.025 mmol/kg bw). A dose of 0.1 mmol/kg achieved the highest peak SNR compared with all other dose levels (P < 0.05). A higher peak SNR was observed in gravity dependent lung (P < 0.05). Despite different injection volumes, transit times of the contrast bolus did not differ between both agents. CONCLUSION: Higher concentrated gadolinium chelates offer no advantage over standard 0.5 M Gd-DTPA for contrast-enhanced 3D MRI of lung perfusion.     

Comparison of bolus and constant infusion methods of gadolinium administration in MR angiography.

PURPOSETo determine whether the method of delivery of gadolinium can alter optimal small-vessel detail in MR angiography.METHODSSix healthy volunteers were studied with MR angiography using both a constant infusion and a bolus method of contrast administration to a total dose of 0.1 mmol/kg. Both three-dimensional time-of-flight and 3-D phase-contrast techniques were used.RESULTSConstant infusion did not prove superior to bolus administration of contrast. With both techniques, gadolinium enhancement uniformly improved visualization of small vessels. Delay from the time of contrast administration to scan acquisition decreased vessel enhancement.CONCLUSIONSBolus administration of gadolinium is sufficient to improve small vessel visualization with MR angiography. When a series of contrast-enhanced images is to be obtained, MR angiographic sequences should be obtained first.     

Coronary arteries at 3.0 T: Contrast-enhanced magnetization-prepared three-dimensional breathhold MR angiography

PURPOSE: To evaluate the efficacy of contrast-enhanced coronary magnetic resonance angiography (MRA) at 3.0 T. MATERIALS AND METHODS: Nine healthy human volunteers were studied on a 3.0-T whole-body MR system. A three-dimensional, breathhold, magnetization-prepared, segmented, gradient-echo sequence was used, with injection of 20 mL gadopentetate dimeglumine for each three-dimensional slab. Imaging parameters were optimized based on computer simulations. Signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), depicted coronary artery length, lumen diameter, and imaging sharpness with contrast agent were evaluated. SNR and CNR were compared to the results from a previous 1.5-T study. RESULTS: A 53% increment in SNR and a 305% enhancement in CNR were measured with contrast. Vessel length and sharpness depicted were higher and the lumen diameter was lower (all P values < 0.05) in postcontrast images. Compared to previous results from 1.5-T, the SNR, CNR, and vessel sharpness were enhanced at 3.0 T with higher spatial resolution. CONCLUSION: Contrast-enhanced, three-dimensional, coronary MRA at 3.0 T is a promising technique for diagnosing coronary artery diseases. Patient studies are necessary to evaluate its clinical utility.